Selection of animals for desirable genotype or potential phenotype properties based on a single nucleotide polymorphism (SNP) in intron 3 of the IGF2 gene

摘要

Selecting (M1) an animal for having desired genotypic or potential phenotypic properties comprises testing the animal, a parent of the animal, or its progeny, for the presence of a nucleic acid modification affecting: (a) the activity of an evolutionary conserved CpG island, located in intron 3 of an IGF2 gene; and/or (b) binding of a nuclear factor to an IGF2 gene. Independent claims are also included for: (1) modulating (M2) mRNA transcription of an IGF2 gene in a cell or organism provided with the gene by modulating the activity of an evolutionarily conserved CpG island located in intron 3 of an IGF2 gene and/or modulating binding of a nuclear factor to an IGF2 gene; (2) identifying (M3) a compound capable of modulating mRNA transcription of an IGF2 gene in a cell or organism provided with the gene comprising: (a) providing a first cell or organism having a nucleic acid modification affecting the activity of an evolutionarily conserved CpG island located in intron 3 of an IGF2 gene and/or affecting binding of a nuclear factor to an IGF2 gene and a second cell or organism not having the modification; and (b) providing the first or second cell or organism with a test compound and determining IGF2 mRNA transcription in the cell or organism; (3) identifying (M4) a compound capable of modulating binding of a nuclear factor to an IGF2 gene comprising: (a) providing a stretch of nucleotides which in the wild type pig, mouse or human IGF2 gene is part of an evolutionarily conserved CpG island, located in intron 3 of the IGF2 gene; (b) providing a mixture of DNA-binding proteins derived from a nuclear extract of a cell; (c) providing a test compound; and (d) determining competition of binding of the mixture of DNA-binding proteins to the stretch of nucleotides in the presence or absence of the test compound; (4) a compound identifiable by M3 or M4; (5) a composition including the compound of (4); and (6) use of a compound of (4) for production of a pharmaceutical for treating obesity or muscle deficiencies and/or for modulating mRNA transcription of an IGF2 gene in a cell or organism. ACTIVITY : Anorectic; Antidiabetic; Muscular-Gen. No biological data given. MECHANISM OF ACTION : Gene Therapy.